Deflazacort in the treatment of haematologic disorders

M. Gobbi, M. Scudeletti

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Glucocorticoids (GCs) exert different activities that are useful for the treatment of several haematologic disorders. The synergistic effect with cytotoxic drugs is important for the therapy of lymphoprolyferative diseases. The inhibition of macrophages prevents acute haemolisys and platelets destruction in autoimmune disorders; moreover GCS are the most important agents for the management of vasculitis complicating cryoglobulinaemia. Deflazacort (DFZ) has similar immunomodulating effects to other GCs but, by contrast, DFZ produces less hypercalciuria and hyperglycaemia than prednisone and dexamethasone. As a result, the adverse effects of prolonged treatment are less with deflazacort. In this paper we report the results obtained with DFZ containing treatment in 27 patients affected by haematological disorders: 12 patients with advanced low or intermediate grade non Hodgkin's lymphoma submitted to 6 courses of combination chemotherapy, 10 patients with acute idiopatic thrombocytopenic purpura and 5 patients with wascular purpura secondary to type 2 cryoglobulinaemia. DFZ was substituted for prednisone or 6-methylprednisolone at a dose calculated in accordance with the PDN: DFZ ratio of 0.78. The results were in accordance within what would be expected with standard treatments containing conventional GCs, whereas in most patients, the side-effects were negligible.

Original languageEnglish
JournalEuropean Journal of Clinical Pharmacology
Volume45
Issue number1 Supplement
DOIs
Publication statusPublished - Jan 1993

Fingerprint

Glucocorticoids
Cryoglobulinemia
Prednisone
Non-Hodgkin's Lymphoma
Therapeutics
Thrombocytopenic Purpura
Hypercalciuria
Purpura
Methylprednisolone
Vasculitis
Combination Drug Therapy
Hyperglycemia
Dexamethasone
deflazacort
Blood Platelets
Macrophages
Pharmaceutical Preparations

Keywords

  • Deflazacort
  • glucocorticoid
  • Haematological disorder
  • immunosuppression

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Deflazacort in the treatment of haematologic disorders. / Gobbi, M.; Scudeletti, M.

In: European Journal of Clinical Pharmacology, Vol. 45, No. 1 Supplement, 01.1993.

Research output: Contribution to journalArticle

@article{7fb099b4f780483aabdfc7e7ca03d0f8,
title = "Deflazacort in the treatment of haematologic disorders",
abstract = "Glucocorticoids (GCs) exert different activities that are useful for the treatment of several haematologic disorders. The synergistic effect with cytotoxic drugs is important for the therapy of lymphoprolyferative diseases. The inhibition of macrophages prevents acute haemolisys and platelets destruction in autoimmune disorders; moreover GCS are the most important agents for the management of vasculitis complicating cryoglobulinaemia. Deflazacort (DFZ) has similar immunomodulating effects to other GCs but, by contrast, DFZ produces less hypercalciuria and hyperglycaemia than prednisone and dexamethasone. As a result, the adverse effects of prolonged treatment are less with deflazacort. In this paper we report the results obtained with DFZ containing treatment in 27 patients affected by haematological disorders: 12 patients with advanced low or intermediate grade non Hodgkin's lymphoma submitted to 6 courses of combination chemotherapy, 10 patients with acute idiopatic thrombocytopenic purpura and 5 patients with wascular purpura secondary to type 2 cryoglobulinaemia. DFZ was substituted for prednisone or 6-methylprednisolone at a dose calculated in accordance with the PDN: DFZ ratio of 0.78. The results were in accordance within what would be expected with standard treatments containing conventional GCs, whereas in most patients, the side-effects were negligible.",
keywords = "Deflazacort, glucocorticoid, Haematological disorder, immunosuppression",
author = "M. Gobbi and M. Scudeletti",
year = "1993",
month = "1",
doi = "10.1007/BF01844200",
language = "English",
volume = "45",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "1 Supplement",

}

TY - JOUR

T1 - Deflazacort in the treatment of haematologic disorders

AU - Gobbi, M.

AU - Scudeletti, M.

PY - 1993/1

Y1 - 1993/1

N2 - Glucocorticoids (GCs) exert different activities that are useful for the treatment of several haematologic disorders. The synergistic effect with cytotoxic drugs is important for the therapy of lymphoprolyferative diseases. The inhibition of macrophages prevents acute haemolisys and platelets destruction in autoimmune disorders; moreover GCS are the most important agents for the management of vasculitis complicating cryoglobulinaemia. Deflazacort (DFZ) has similar immunomodulating effects to other GCs but, by contrast, DFZ produces less hypercalciuria and hyperglycaemia than prednisone and dexamethasone. As a result, the adverse effects of prolonged treatment are less with deflazacort. In this paper we report the results obtained with DFZ containing treatment in 27 patients affected by haematological disorders: 12 patients with advanced low or intermediate grade non Hodgkin's lymphoma submitted to 6 courses of combination chemotherapy, 10 patients with acute idiopatic thrombocytopenic purpura and 5 patients with wascular purpura secondary to type 2 cryoglobulinaemia. DFZ was substituted for prednisone or 6-methylprednisolone at a dose calculated in accordance with the PDN: DFZ ratio of 0.78. The results were in accordance within what would be expected with standard treatments containing conventional GCs, whereas in most patients, the side-effects were negligible.

AB - Glucocorticoids (GCs) exert different activities that are useful for the treatment of several haematologic disorders. The synergistic effect with cytotoxic drugs is important for the therapy of lymphoprolyferative diseases. The inhibition of macrophages prevents acute haemolisys and platelets destruction in autoimmune disorders; moreover GCS are the most important agents for the management of vasculitis complicating cryoglobulinaemia. Deflazacort (DFZ) has similar immunomodulating effects to other GCs but, by contrast, DFZ produces less hypercalciuria and hyperglycaemia than prednisone and dexamethasone. As a result, the adverse effects of prolonged treatment are less with deflazacort. In this paper we report the results obtained with DFZ containing treatment in 27 patients affected by haematological disorders: 12 patients with advanced low or intermediate grade non Hodgkin's lymphoma submitted to 6 courses of combination chemotherapy, 10 patients with acute idiopatic thrombocytopenic purpura and 5 patients with wascular purpura secondary to type 2 cryoglobulinaemia. DFZ was substituted for prednisone or 6-methylprednisolone at a dose calculated in accordance with the PDN: DFZ ratio of 0.78. The results were in accordance within what would be expected with standard treatments containing conventional GCs, whereas in most patients, the side-effects were negligible.

KW - Deflazacort

KW - glucocorticoid

KW - Haematological disorder

KW - immunosuppression

UR - http://www.scopus.com/inward/record.url?scp=0027487021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027487021&partnerID=8YFLogxK

U2 - 10.1007/BF01844200

DO - 10.1007/BF01844200

M3 - Article

VL - 45

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 1 Supplement

ER -